Evonik Oxeno expands production capacity for Elatur plasticizers
Evonik Oxeno is significantly expanding the production capacities for its INA-based plasticizers ELATUR CH (DINCH) and ELATUR DINCD. These products were launched in recent years and have now become the new standard plasticizers for Evonik Oxeno customers.
“This capacity expansion is another important milestone in the diversification of our plasticizer portfolio. To meet the growing demand for these products, we will start this year,” said Frank Beißmann, Managing Director of Evonik Oxeno.
The capacity expansion will be integrated into the existing C4 plant network in Marl.
“With the expansion, we can ensure that our customers receive a high level of delivery reliability and quality from European production,” said Roland Pietz, Vice President Oxo Alcohols and Plasticizers at Evonik Oxeno.
In addition to the ELATUR product line, VESTINOL 9 (DINP) remains an important component of Evonik Oxeno’s product portfolio.
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Wanhua Chemical Is Fighting Counterfeits While Raising Prices
-
Lier Chemical Gains Momentum as Chlorantraniliprole Supply Stabilizes
-
Wanhua Chemical's 240,000-ton/year Iron Phosphate Project Approved
-
Pharmaceutical State-Owned Enterprise Acquires Leading Pesticide Company for RMB 5.656 Billion, Betting on Synthetic Biology Industrialization
-
LB Group Accelerates Overseas Investment: Securing Mines in Western Australia and Building a Plant in Malaysia
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
BASF Ludwigshafen Workforce Falls Below 30,000, Lowest Level in 72 Years
-
Production Down 6%, Profits Cut by $3.7 Billion: Middle East Conflict Hits ExxonMobil Hard
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
BASF and Hannong Chemical Joint Venture Nonionic Surfactant Plant Begins Operation in South Korea
Recommend Reading
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
-
Novo Nordisk’s Oral Wegovy Wins EU Approval as Weight-Loss Competition Shifts from Injections to Pills
-
Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market
-
Lilly Bets US$3 Billion on China While Simultaneously Cracking Down on the Gray Market for Weight-Loss Drugs
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition
-
Strong Supply and Demand Driving Lithium Carbonate Price Fluctuations
-
FDA Reopens the Raw Manure Debate
-
FSANZ Moves Toward Approval of Insect-Resistant Corn COR121
-
Tight Supply Supports Maleic Anhydride Prices in July, Circulation Volume May Gradually Recover in August
-
Supply and Demand Dynamics Continue, Formic Acid Prices Rise